Tirzepatide does not work like a stimulant or like a fat blocker or like insulin. It works by mimicking two hormones your gut already makes. Knowing the mechanism helps make sense of both the effects and the side effects.

The Two Hormones

When you eat, your gut releases a set of signalling hormones called incretins. The two main ones are:

  • GLP-1 (glucagon-like peptide-1)
  • GIP (glucose-dependent insulinotropic polypeptide)

Both are released by special cells in the small intestine. Both travel in the bloodstream and act on the pancreas, the brain, and the gut. They are the body's natural messengers that say 'food has arrived, get ready'.

What Each Hormone Does

GLP-1

  • Tells the pancreas to release insulin (only when blood glucose is up)
  • Tells the pancreas to release less glucagon (a hormone that raises blood sugar)
  • Slows down the stomach so food stays there longer, releasing slowly into the small intestine
  • Acts on the brain (specifically the hypothalamus) to reduce appetite

GIP

  • Also tells the pancreas to release insulin in response to food
  • Influences how fat tissue stores and releases energy
  • Has emerging evidence of effects on the brain that complement GLP-1

In people with obesity or type 2 diabetes, the response to these hormones is often blunted. The signal is there but the body does not act on it as strongly. Tirzepatide essentially turns the volume back up.

What Tirzepatide Does

Tirzepatide is a single molecule designed to activate both the GLP-1 receptor and the GIP receptor. By binding to both, it amplifies the natural incretin response. Practical effects:

Reduced appetite

This is the effect most people notice first. The medication acts on the appetite centres in the brain, reducing the urge to eat and shortening the duration of cravings. People often describe it as 'the food noise going quiet'.

Increased satiety

You feel full sooner and stay full longer after a meal. Combined with the slowed gastric emptying, portion sizes naturally drop without conscious effort.

Better blood sugar control

Insulin is released in a more matched way when food arrives, and the post-meal glucose spike is blunted. For people with type 2 diabetes this is the primary therapeutic effect.

Improved glucose handling between meals

Reduced glucagon release means the liver produces less glucose between meals, helping baseline blood sugar.

Possible effects on fat metabolism

Through GIP activation, there are signs that tirzepatide also affects how fat tissue handles energy. This is one of the proposed reasons it appears to produce stronger weight effects than GLP-1 alone.

Talk To A Doctor About Whether It Fits You

An online consultation reviews your medical history and decides whether tirzepatide is appropriate, and what dose to start at.

Start Consultation

Why Two Pathways Beat One

Imagine your appetite is controlled by two switches. GLP-1 acts on one, GIP acts on the other. Older medications like Ozempic and Wegovy press one switch. Mounjaro presses both. The result, in clinical trials, is a stronger effect on blood sugar, appetite, and weight.

This is not just additive in theory. The SURPASS trials (for diabetes) and the SURMOUNT trials (for weight management) showed tirzepatide produces consistently larger reductions in both HbA1c and body weight than the GLP-1-only comparator, at maximum tolerated doses.

Why It Takes Time

The medication starts at 2.5 mg weekly, well below the therapeutic dose, and steps up over months. The slow titration is because of the gut effects. Your stomach is being asked to empty more slowly than it is used to. That feels uncomfortable in the early weeks, often as nausea, and the body needs time to adapt.

The titration also lets you find your tolerated dose. Not everyone needs to go all the way to 15 mg. Many people respond well at 5 mg or 10 mg and stay there.

What The Medication Cannot Do

  • It cannot replace food choices. Most appetite reduction is mathematical, eating less. The medication makes eating less easier. It does not make poor food choices healthy.
  • It cannot replace movement. Muscle is at risk during weight loss. Resistance training and protein intake during treatment matter.
  • It cannot fix the cause of obesity or diabetes if those have specific drivers (medication side effects, untreated sleep apnoea, hormonal conditions). A consultation looks for these.

How Long Does It Last In The Body

Tirzepatide has a half life of around five days, which is what makes the weekly injection possible. After injection, the level peaks at around 24 to 72 hours and stays elevated for the rest of the week. By the next injection, much of the previous dose is still active.

This long action is why missing a dose is not a crisis. If you remember within four days of your usual injection day, take it. If more than four days, skip and resume on the next regular day. See the schedule.

Related Reading

Frequently Asked

Not directly. It reduces appetite and slows gastric emptying so you eat less. The energy deficit then leads to fat loss. There is also evidence of improvements in how the body uses glucose and fat, which contributes.

The body needs time to adapt to the slowed gastric emptying and the altered hormone signalling. Starting at 2.5 mg and titrating up gives the gut a chance to adjust and reduces nausea.

Yes, but indirectly. By reducing food intake and improving glucose handling, the medication shifts how the body uses energy. There is no evidence that it directly increases metabolic rate the way a stimulant would.

Older medications either acted on a single pathway or worked through general mechanisms like fat absorption. Mounjaro acts on two complementary gut hormones at once, producing larger effects on both blood sugar and weight in clinical trials.